View Item 

Show simple item record

Sex Differences in the Use of Oral Anticoagulants for Atrial Fibrillation: A Report From the National Cardiovascular Data Registry (NCDR®) PINNACLE Registry
dc.contributor.authorThompson, Lauren E.
dc.contributor.authorMaddox, Thomas M.
dc.contributor.authorLei, Lanyu
dc.contributor.authorGrunwald, Gary K.
dc.contributor.authorBradley, Steven M.
dc.contributor.authorPeterson, Pamela N.
dc.contributor.authorMasoudi, Frederick A.
dc.contributor.authorTurchin, Alexander
dc.contributor.authorSong, Yang
dc.contributor.authorDoros, Gheorghe
dc.contributor.authorDavis, Melinda B.
dc.contributor.authorDaugherty, Stacie L.
dc.date.accessioned2018-03-07T18:24:38Z
dc.date.available2018-08-28T15:28:59Zen
dc.date.issued2017-07
dc.identifier.citationThompson, Lauren E.; Maddox, Thomas M.; Lei, Lanyu; Grunwald, Gary K.; Bradley, Steven M.; Peterson, Pamela N.; Masoudi, Frederick A.; Turchin, Alexander; Song, Yang; Doros, Gheorghe; Davis, Melinda B.; Daugherty, Stacie L. (2017). "Sex Differences in the Use of Oral Anticoagulants for Atrial Fibrillation: A Report From the National Cardiovascular Data Registry (NCDR®) PINNACLE Registry." Journal of the American Heart Association (7): n/a-n/a.
dc.identifier.issn2047-9980
dc.identifier.issn2047-9980
dc.identifier.urihttps://hdl.handle.net/2027.42/142481
dc.publisherWiley Periodicals, Inc.
dc.subject.otherwomen
dc.subject.otheranticoagulants
dc.subject.otheratrial fibrillation
dc.subject.othernon‐vitamin K oral anticoagulants
dc.subject.othersex differences
dc.subject.otherwarfarin
dc.titleSex Differences in the Use of Oral Anticoagulants for Atrial Fibrillation: A Report From the National Cardiovascular Data Registry (NCDR®) PINNACLE Registry
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelCardiovascular Medicine
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/142481/1/jah32348.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/142481/2/jah32348_am.pdf
dc.identifier.doi10.1161/JAHA.117.005801
dc.identifier.sourceJournal of the American Heart Association
dc.identifier.citedreferencePiyaskulkaew C, Singh T, Szpunar S, Saravolatz L II, Rosman H. CHA(2)DS(2)‐VASc versus CHADS(2) for stroke risk assessment in low‐risk patients with atrial fibrillation: a pilot study from a single center of the NCDR‐PINNACLE registry. J Thromb Thrombolysis. 2014; 37: 400 – 403.
dc.identifier.citedreferenceDentali F, Riva N, Crowther M, Turpie AG, Lip GY, Ageno W. Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta‐analysis of the literature. Circulation. 2012; 126: 2381 – 2391.
dc.identifier.citedreferenceRomanelli RJ, Nolting L, Dolginsky M, Kym E, Orrico KB. Dabigatran versus warfarin for atrial fibrillation in real‐world clinical practice. Circ Cardiovasc Qual Outcomes. 2016; 9: 126 – 134.
dc.identifier.citedreferenceNCDR ® PINNACLE Registry ® v1.3 full data dictionary. 2014.
dc.identifier.citedreferenceChan PS, Oetgen WJ, Spertus JA. The improving continuous cardiac care (IC3) program and outpatient quality improvement. Am J Med. 2010; 123: 217 – 219.
dc.identifier.citedreferenceMasoudi FA, Ponirakis A, Yeh RW, Maddox TM, Beachy J, Casale PN, Curtis JP, De Lemos J, Fonarow G, Heidenreich P, Koutras C, Kremers M, Messenger J, Moussa I, Oetgen WJ, Roe MT, Rosenfield K, Shields TP Jr, Spertus JA, Wei J, White C, Young CH, Rumsfeld JS. Cardiovascular care facts: a report from the National Cardiovascular Data Registry: 2011. J Am Coll Cardiol. 2013; 62: 1931 – 1947.
dc.identifier.citedreferenceMaddox TM, Borden WB, Tang F, Virani SS, Oetgen WJ, Mullen JB, Chan PS, Casale PN, Douglas PS, Masoudi FA, Farmer SA, Rumsfeld JS. Implications of the 2013 ACC/AHA cholesterol guidelines for adults in contemporary cardiovascular practice insights from the NCDR PINNACLE registry. J Am Coll Cardiol. 2014; 64: 2183 – 2192.
dc.identifier.citedreferenceMessenger JC, Ho KKL, Young CH, Slattery LE, Draoui JC, Curtis JP, Dehmer GJ, Grover FL, Mirro MJ, Reynolds MR, Rokos IC, Spertus JA, Wang TY, Winston SA, Rumsfeld JS, Masoudi FA. The National Cardiovascular Data Registry (NCDR) data quality brief: the NCDR data quality program in 2012. J Am Coll Cardiol. 2012; 60: 1484 – 1488.
dc.identifier.citedreferenceNCDR PINNACLE Registry v1.3 full data dictionary. 2015.
dc.identifier.citedreferencePuurunen MK, Kiviniemi T, Schlitt A, Rubboli A, Dietrich B, Karjalainen P, Nyman K, Niemelä M, Lip GYH, Airaksinen KEJ. CHADS 2, CHA 2 DS 2 ‐VASc and HAS‐BLED as predictors of outcome in patients with atrial fibrillation undergoing percutaneous coronary intervention. Thromb Res. 2014; 133: 560 – 566.
dc.identifier.citedreferenceFuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey J‐Y, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S; ACC/AHA Task Force Members, Smith SC, Jacobs AK, Adams CD, Anderson JL, Antman EM, Halperin JL, Hunt SA, Nishimura R, Ornato JP, Page RL, Riegel B; ESC Committee for Practice Guidelines, Priori SG, Blanc J‐J, Budaj A, Camm AJ, Dean V, Deckers JW, Despres C, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo JL, Zamorano JL. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation—executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006; 114: e257 – e354.
dc.identifier.citedreferenceGage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001; 285: 2864 – 2870.
dc.identifier.citedreferenceGreenland S. Model‐based estimation of relative risks and other epidemiologic measures in studies of common outcomes and in case‐control studies. Am J Epidemiol. 2004; 160: 301 – 305.
dc.identifier.citedreferenceZou G. A modified Poisson regression approach to prospective studies with binary data. Am J Epidemiol. 2004; 159: 702 – 706.
dc.identifier.citedreferenceYelland LN, Salter AB, Ryan P. Performance of the modified Poisson regression approach for estimating relative risks from clustered prospective data. Am J Epidemiol. 2011; 174: 984 – 992.
dc.identifier.citedreferenceZou GY, Donner A. Extension of the modified Poisson regression model to prospective studies with correlated binary data. Stat Methods Med Res. 2013; 22: 661 – 670.
dc.identifier.citedreferenceMarzec LN, Katz DF, Maddox TM, Turakhia MP, Gehi AK, O’Brien EC, Lubitz SA, Varosy PD, Hsu JC. Effects of guideline recommended change in use of the CHADS2 to the CHA2DS2‐VASc score for the assessment of thromboembolic risk in atrial fibrillation patients at low to moderate risk of stroke: An analysis from the NCDR PINNACLE AF Registry. HRS 2015 Abstract Presentation. 2015.
dc.identifier.citedreferenceMason PK, Lake DE, DiMarco JP, Ferguson JD, Mangrum JM, Bilchick K, Moorman LP, Moorman JR. Impact of the CHA 2 DS 2 ‐VASc score on anticoagulation recommendations for atrial fibrillation. Am J Med. 2012; 125: 603.e601 – 603.e606.
dc.identifier.citedreferenceRenda G, di Nicola M, De Caterina R. Net clinical benefit of non‐vitamin K antagonist oral anticoagulants versus warfarin in phase III atrial fibrillation trials. Am J Med. 2015; 9: 1007 – 1014.
dc.identifier.citedreferencePiccini JP, Simon DN, Steinberg BA, Thomas L, Allen LA, Fonarow GC, Gersh B, Hylek E, Kowey PR, Reiffel JA, Naccarelli GV, Chan PS, Spertus JA, Peterson ED. Differences in clinical and functional outcomes of atrial fibrillation in women and men: two‐year results from the ORBIT‐AF registry. JAMA Cardiol. 2016; 1: 282 – 291.
dc.identifier.citedreferenceLip GYH, Laroche C, Boriani G, Cimaglia P, Dan G‐A, Santini M, Kalarus Z, Rasmussen LH, Popescu MI, Tica O, Hellum CF, Mortensen B, Tavazzi L, Maggioni AP. Sex‐related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: a report from the Euro Observational Research Programme Pilot Survey on Atrial Fibrillation. Europace. 2015; 17: 24 – 31.
dc.identifier.citedreferenceLip GY, Rushton‐Smith SK, Goldhaber SZ, Fitzmaurice DA, Mantovani LG, Goto S, Haas S, Bassand JP, Camm AJ, Ambrosio G, Jansky P, Al Mahmeed W, Oh S, van Eickels M, Raatikainen P, Steffel J, Oto A, Kayani G, Accetta G, Kakkar AK. Does sex affect anticoagulant use for stroke prevention in nonvalvular atrial fibrillation? The prospective global anticoagulant registry in the FIELD‐atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2015; 8: S12 – S20.
dc.identifier.citedreferenceVolgman AS, Manankil MF, Mookherjee D, Trohman RG. Women with atrial fibrillation: greater risk, less attention. Gend Med. 2009; 6: 419 – 432.
dc.identifier.citedreferenceDecker C, Garavalia L, Garavalia B, Simon T, Loeb M, Spertus JA, Daniel WC. Exploring barriers to optimal anticoagulation for atrial fibrillation: interviews with clinicians. J Multidiscip Healthc. 2012; 5: 129 – 135.
dc.identifier.citedreferenceDaugherty SL, Thompson LE, Kim S, Rao SV, Subherwal S, Tsai TT, Messenger JC, Masoudi FA. Patterns of use and comparative effectiveness of bleeding avoidance strategies in men and women following percutaneous coronary interventions: an observational study from the National Cardiovascular Data Registry. J Am Coll Cardiol. 2013; 61: 2070 – 2078.
dc.identifier.citedreferenceDaugherty SL, Magid DJ. Do sex differences exist in patient preferences for cardiovascular testing? Ann Emerg Med. 2011; 57: 561 – 562.
dc.identifier.citedreferenceMcSweeney JC, Rosenfeld AG, Abel WM, Braun LT, Burke LE, Daugherty SL, Fletcher GF, Gulati M, Mehta LS, Pettey C, Reckelhoff JF. Preventing and experiencing ischemic heart disease as a woman: state of the science: a scientific statement from the American Heart Association. Circulation. 2016; 133: 1302 – 1331.
dc.identifier.citedreferenceKalra A, Pokharel Y, Glusenkamp N, Wei J, Kerkar PG, Oetgen WJ, Virani SS. Gender disparities in cardiovascular care access and delivery in India: insights from the American College of Cardiology’s PINNACLE India Quality Improvement Program (PIQIP). Int J Cardiol. 2016; 215: 248 – 251.
dc.identifier.citedreferenceKalra L, Yu G, Perez I, Lakhani A, Donaldson N. Prospective cohort study to determine if trial efficacy of anticoagulation for stroke prevention in atrial fibrillation translates into clinical effectiveness. BMJ. 2000; 320: 1236 – 1239.
dc.identifier.citedreferenceSamsa GP, Matchar DB, Goldstein LB, Bonito AJ, Lux LJ, Witter DM, Bian J. Quality of anticoagulation management among patients with atrial fibrillation: results of a review of medical records from 2 communities. Arch Intern Med. 2000; 160: 967 – 973.
dc.identifier.citedreferenceFang MC, Singer DE, Chang Y, Hylek EM, Henault LE, Jensvold NG, Go AS. Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation. 2005; 112: 1687 – 1691.
dc.identifier.citedreferencePoli D, Antonucci E, Grifoni E, Abbate R, Gensini GF, Prisco D. Gender differences in stroke risk of atrial fibrillation patients on oral anticoagulant treatment. Thromb Haemost. 2009; 101: 938 – 942.
dc.identifier.citedreferenceEmdin CA, Wong CX, Hsiao AJ, Altman DG, Peters SA, Woodward M, Odutayo AA. Atrial fibrillation as risk factor for cardiovascular disease and death in women compared with men: systematic review and meta‐analysis of cohort studies. BMJ. 2016; 352: h7013.
dc.identifier.citedreferenceLip GY, Eikelboom J, Yusuf S, Shestakovska O, Hart RG, Connolly S. Modification of outcomes with aspirin or apixaban in relation to female and male sex in patients with atrial fibrillation: a secondary analysis of the AVERROES study. Stroke. 2014; 45: 2127 – 2130.
dc.identifier.citedreferenceAgarwal S, Bennett D, Smith DJ. Predictors of warfarin use in atrial fibrillation patients in the inpatient setting. Am J Cardiovasc Drugs. 2010; 10: 37 – 48.
dc.identifier.citedreferenceHumphries KH, Kerr CR, Connolly SJ, Klein G, Boone JA, Green M, Sheldon R, Talajic M, Dorian P, Newman D. New‐onset atrial fibrillation: sex differences in presentation, treatment, and outcome. Circulation. 2001; 103: 2365 – 2370.
dc.identifier.citedreferenceChan PS, Oetgen WJ, Buchanan D, Mitchell K, Fiocchi FF, Tang F, Jones PG, Breeding T, Thrutchley D, Rumsfeld JS, Spertus JA. Cardiac performance measure compliance in outpatients: the American College of Cardiology and National Cardiovascular Data Registry’s PINNACLE (Practice Innovation and Clinical Excellence) program. J Am Coll Cardiol. 2010; 56: 8 – 14.
dc.identifier.citedreferenceBhave PD, Lu X, Girotra S, Kamel H, Vaughan Sarrazin MS. Race‐ and sex‐related differences in care for patients newly diagnosed with atrial fibrillation. Heart Rhythm. 2015; 12: 1406 – 1412.
dc.identifier.citedreferenceShantsila E, Wolff A, Lip G, Lane D. Gender differences in stroke prevention in atrial fibrillation in general practice: using the GRASP‐AF audit tool. Int J Clin Pract. 2015; 69: 840 – 845.
dc.identifier.citedreferenceJönsson AC, Ek J, Kremer C. Outcome of men and women after atrial fibrillation and stroke. Acta Neurol Scand. 2015; 132: 125 – 131.
dc.identifier.citedreferenceCosma Rochat M, Waeber G, Wasserfallen JB, Nakov K, Aujesky D. Hospitalized women experiencing an episode of excessive oral anticoagulation had a higher bleeding risk than men. J Womens Health. 2009; 18: 321 – 326.
dc.identifier.citedreferenceLane DA, Lip G. Female gender is a risk factor for stroke and thromboembolism in atrial fibrillation patients. Thromb Haemost. 2009; 101: 802 – 805.
dc.identifier.citedreferenceLip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor‐based approach: the Euro Heart Survey on Atrial Fibrillation. Chest. 2010; 137: 263 – 272.
dc.identifier.citedreferenceCamm AJ, Kirchhof P, Lip GYH, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al‐Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A, Gorenek B, Heldal M, Hohloser SH, Kolh P, Le Heuzey J‐Y, Ponikowski P, Rutten FH, Vahanian A, Auricchio A, Bax J, Ceconi C, Dean V, Filippatos G, Funck‐Brentano C, Hobbs R, Kearney P, McDonagh T, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Vardas PE, Widimsky P, Vardas PE, Agladze V, Aliot E, Balabanski T, Blomstrom‐Lundqvist C, Capucci A, Crijns H, Dahlöf B, Folliguet T, Glikson M, Goethals M, Gulba DC, Ho SY, Klautz RJM, Kose S, McMurray J, Perrone Filardi P, Raatikainen P, Salvador MJ, Schalij MJ, Shpektor A, Sousa J, Stepinska J, Uuetoa H, Zamorano JL, Zupan I. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010; 31: 2369 – 2429.
dc.identifier.citedreferenceJanuary CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy CW. AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary. Circulation. 2014; 130: 2071 – 2104.
dc.identifier.citedreferenceAvgil Tsadok M, Jackevicius CA, Rahme E, Humphries KH, Pilote L. Sex differences in dabigatran use, safety, and effectiveness in a population‐based cohort of patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2015; 8: 593 – 599.
dc.identifier.citedreferencePatel KK, Mehdirad AA, Lim MJ, Ferreira SW, Mikolajczak PC, Stolker JM. Beyond warfarin: a patient‐centered approach to selecting novel oral anticoagulants for stroke prevention in atrial fibrillation. J Hosp Med. 2014; 9: 400 – 406.
dc.identifier.citedreferencePancholy SB, Sharma PS, Pancholy DS, Patel TM, Callans DJ, Marchlinski FE. Meta‐analysis of gender differences in residual stroke risk and major bleeding in patients with nonvalvular atrial fibrillation treated with oral anticoagulants. Am J Cardiol. 2014; 113: 485 – 490.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
jah32348.pdf
Size:
917.9KB
Format:
PDF
View/Open
Name:
jah32348_am.pdf
Size:
416.4KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.